Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Dideoxycytidine for AIDS

Executive Summary

HHS is seeking an industry sponsor to collaborate in the preclinical and clinical development of the antiviral for treatment of AIDS. In the Oct. 14 Federal Register, HHS reported that National Cancer Institute scientists have shown dideoxycytidine "is effective in inhibiting in vitro growth of HTLV-III, the etiologic agent of AIDS." The agency said the industry sponsor will be granted an exclusive royalty-bearing license, while the U.S. government will receive "reasonable royalties".

You may also be interested in...



EMA Consults On Using Registry Studies As RWE Source

A draft EU guideline explains how disease registries can be used to supplement evidence in the pre-authorization phase and provide infrastructure for post-authorization evidence generation.

Italy: Pharma May Have To Disclose Confidential Info Under New Pricing Rules

Drug companies have their last chance to negotiate which documents and information Italy’s regulator, AIFA, will be entitled to request of them when they submit pricing and reimbursement applications.

Sandoz Looks Ahead To Biosimilar Opportunities

Sandoz sees key opportunities ahead in both the US and Canadian biosimilars markets, the firm’s US vice-president for marketing, market access and patient services, Sheila Frame, tells Generics Bulletin in the second part of an exclusive interview.

UsernamePublicRestriction

Register

ID1128360

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel